Trial Profile

A Post-Authorisation Safety Study Patient Registry of Patients With High-risk Neuroblastoma Being Treated With the Monoclonal Antibody Dinutuximab Beta

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 15 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dinutuximab beta (Primary) ; Antihistamines; Gabapentin; Interleukin-2; Non-opioid analgesics; Opioid analgesics; Pregabalin; Tretinoin
Indications Neuroblastoma
Focus Adverse reactions
Sponsors EUSA Pharma

Most Recent Events

29 Sep 2020 Planned End Date changed from 15 Jan 2032 to 15 Jun 2032.
29 Sep 2020 Planned primary completion date changed from 30 Oct 2031 to 31 Mar 2032.
29 Sep 2020 Status changed from active, no longer recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com